SCHEMBL20719611

SCHEMBL20719611

CC(=O)OCCc1ccc(Br)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.38
MET P08581 2/20 0.37
ALDH1A1 P00352 3/20 0.36
TSHR P16473 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MEN1 O00255 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
KMT2A Q03164 2/20 0.36
HTT P42858 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
ALOX15 P16050 1/20 0.36
NFKB1 P19838 1/20 0.36
THPO P40225 1/20 0.36
BLM P54132 1/20 0.36
PMP22 Q01453 1/20 0.36
HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30554484 1.00 RAD52 (0.38) RAD52METALDH1A1TSHRL3MBTL1
SCHEMBL27718312 0.82 TSHR (0.51) RAD52METALDH1A1TSHRL3MBTL1
SCHEMBL20943263 0.81 ALDH1A1 (0.54) ALDH1A1L3MBTL1MEN1KMT2ALMNA
SCHEMBL20943257 0.78 AOC3 (0.41) RAD52METALDH1A1TSHRL3MBTL1
SCHEMBL1873120 0.78 ALDH1A1 (0.48) ALDH1A1TSHRL3MBTL1MEN1CYP1A2
SCHEMBL2455016 0.78 CYP11B1 (0.40) L3MBTL1NFKB1CYP11B1
SCHEMBL4668894 0.78 ALDH1A1 (0.45) RAD52ALDH1A1TSHRL3MBTL1MEN1
Hydrochloric Acid SCHEMBL20719485 0.77 AOC3 (0.40) RAD52METALDH1A1TSHRL3MBTL1
SCHEMBL20719579 0.77 ACACB (0.43) METALDH1A1MAPT
Hydrochloric Acid SCHEMBL30554546 0.77 AOC3 (0.40) RAD52METALDH1A1TSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3447058-B1 NOVEL BROAD-SPECTRUM BETA-LACTAMASE INHIBITOR WUHAN VISION PHARMACEUTICAL TECH CO LTD (CN) 2023-10-11 EP disclosed
US-10479805-B2 Beta-lactamase inhibitor WUHAN VISION PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2019-11-19 US disclosed
US-20190048027-A1 BETA-LACTAMASE INHIBITOR WUHAN VISION PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190048027-A1 BETA-LACTAMASE INHIBITOR ALPI, MGAM, LCT RAD52 1392/4885MET 3618/4885ALDH1A1 494/4885
US-10479805-B2 Beta-lactamase inhibitor ALPI, MGAM, LCT RAD52 1392/4885MET 3618/4885ALDH1A1 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.